Book description
A practice-oriented desktop reference for medical professionals,
toxicologists and pharmaceutical researchers, this handbook provides
systematic coverage of the metabolic pathways of all major classes of
xenobiotics in the human body. The first part comprehensively reviews
the main enzyme systems involved in biotransformation and how they are
orchestrated in the body, while parts two to four cover the three
main classes of xenobiotics: drugs, natural products, environmental
pollutants. The part on drugs includes more than 300 substances from
five major therapeutic groups (central nervous system, cardiovascular
system, cancer, infection, and pain) as well as most drugs of abuse
including nicotine, alcohol and ?designer? drugs. Selected,
well-documented case studies from the most important xenobiotics classes
illustrate general principles of metabolism, making this equally useful
for teaching courses on pharmacology, drug metabolism or molecular
toxicology.
Of particular interest, and unique to this volume is the inclusion of a
wide range of additional xenobiotic compounds, including food
supplements, herbal preparations, and agrochemicals. Pavel Anzenbacher
heads the Department of Pharmacology at Palacky University, Olomouc
(Czech Republic) and is vicepresident of the Czech Society of Clinical
and Experimental Pharmacology and Toxicology. Having obtained his
academic degrees from Charles University, Prague and from the Academy of
Sciences of the Czech Republic he joined the Faculty of Medicine at
Palacky University. His scientific contacts and stays have included e.
g. the Princeton University, Vanderbilt University, Nashville,
University of Connecticut, INSERM Montpellier, University of Lubeck,
Technical University Berlin and Jagellonian University Cracow. Professor
Anzenbacher has authored over 150 original scientific publications and
has, among other honours, received the Fogarty Award of the USPHS.
Ulrich M. Zanger is deputy head of the Dr. Margarete Fischer-Bosch
Institute of Clinical Pharmacology, Stuttgart (Germany). A chemist by
training, he began to work on drug metabolism at the Biocenter of the
University of Basel, Switzerland, where he obtained a PhD
degree in biochemistry. He undertook postdoctoral studies at the
Southwestern Medical Center at Dallas, Texas, before returning to Basel
and later moving to Stuttgart. His major research interests are in human
drug metabolizing cytochromes P450 and in basic and clinical aspects
of pharmacogenetics/genomics. Professor Zanger has authored more than
130 scientific articles and is lecturing in pharmacology and toxicology
at the University of Tubingen.
